Endocrine News Podcast · Endocrine Society

ENP103: Type 1 Diabetes: Immunotherapies and Early Detection

·23 min

The Endocrine News Podcast opens with the Endocrine Society’s 12th annual Type 1 Diabetes Fellows Series program and the education and career-development goals behind it. Dr. Desmond Schatz joins to discuss a talk on immunotherapies for type 1 diabetes and the importance of early detection and screening. He explains that treatment is easier and more meaningful when some endogenous insulin production remains. Schatz walks through the staging framework for type 1 diabetes. Stage 0 is represented by a single autoantibody marker in peripheral blood. Stage 1 is beta cell autoimmunity with two or more autoantibodies and normal glycemia. Stage 2 is progression with two or more antibodies plus abnormal glucose tolerance or blood glucose outside the normal range. Stage 3 is symptomatic, early-onset type 1 diabetes. He notes that most studies to date have focused on stage 3. The reason is practical: these are the patients in whom preservation of C-peptide can be measured more directly. He points to the DCCT and EDIC studies as evidence that C-peptide preservation is linked to fewer later complications. He also notes that patients who maintain C-peptide are generally easier to manage and have less hypoglycemia. That makes C-peptide preservation useful both as an endpoint and as a sign that earlier intervention might work. The episode then moves into prevention research. Schatz describes several antigen-based and immunomodulatory approaches, including B-cell-directed therapy such as rituximab, polyclonal T-cell antibodies such as antithymocyte globulin, CTLA-4 immunoglobulins, and anti-CD3 approaches. He says these agents have shown the ability to preserve C-peptide in new-onset patients, at least for a year or two. The larger implication is that if a therapy helps after diagnosis, it may have a role even earlier, in stage 1 or stage 2. The conversation stays careful throughout. It is hopeful, but not overblown. It keeps returning to the gap between promising signals and real-world implementation. The episode ends by emphasizing that early detection and screening may be central if the field wants to move treatment upstream rather than only respond after symptoms begin.

As heard by us

A focused look at how early detection could widen the treatment window for type 1 diabetes.

The episode gives a clear look at type 1 diabetes before symptoms show up, with Dr. Desmond Schatz's talk on early detection, screening, and immunotherapies setting out the stages of the disease and why intervention matters.

Read the full review in PlayNext →

Why you'd press play

You want the clinical case for catching type 1 diabetes early, before the symptomatic stage.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify